lobbying


BP Hosts Annual General Meeting Amid Questions on Climate Change

, climate accountability campaign manager

Tomorrow, BP holds its Annual General Meeting (AGM) in London. BP shareholders are gathering at a time of mounting pressure on major fossil fuel companies to begin to plan for a world free from carbon pollution—as evidenced by last week’s vote by a majority of Occidental Petroleum shareholders in favor of a resolution urging the company to assess how the company’s business will be affected by climate change. Read more >

Bookmark and Share

ConocoPhillips Shareholders to Consider Climate-Related Lobbying and Executive Perks

, climate accountability campaign manager

Today ConocoPhillips holds a virtual annual shareholders’ meeting, where the company will face two significant climate-related resolutions. These resolutions intersect with some of the key findings and recommendations of UCS’s 2016 report The Climate Accountability Scorecard. ConocoPhillips responded to the report shortly after its release, and UCS has been engaging with company officials over the company’s climate-related positions and actions since then. We’ll be following the shareholders’ meeting with keen interest. Read more >

©corlaffra/Shutterstock.com
Bookmark and Share

Congress Wants to Keep the Feds Out of Fracking: Bad Idea

, director, Center for Science & Democracy

In July, before our Science and Democracy forum on fracking, I wrote about the important role the federal government has to play, working with state and local government, to address the risks of hydraulic fracturing and the associated development of unconventional oil and gas resources. Apparently, members of the U.S. House of Representatives didn’t read my blog. Read more >

Bookmark and Share

The Future Health of Scientific Integrity is at Stake in New FDA Law

, sr. Washington rep., Center for Science & Democracy

The news these days has rightly focused on the Supreme Court’s landmark decision on access to health care.  But with scant media attention, Congress on June 26 sent a bill to the President that is just as important  to the health and well-being of each and every American family, and the future of scientific integrity at the Food and Drug Administration. Read more >

Bookmark and Share

Money Talks, and What It’s Saying May Harm the FDA

, sr. Washington rep., Center for Science & Democracy

Any way you look at it, $700 million is a lot of cash. That’s the amount that industries regulated by the FDA have spent since 2009 lobbying Congress and the Executive Branch. That investment is paying off as Congress now considers must-pass legislation that governs how the FDA uses science to evaluate prescription drugs and medical devices. Read more >

Bookmark and Share